Tuesday, October 26, 2021
HomeUpdatesCOVID-19COVAXIN production volumes ramped up by Bharat Biotech, by additional 200 million

COVAXIN production volumes ramped up by Bharat Biotech, by additional 200 million

Covaxin,covaxin vs covishield,covaxin vaccine,covaxin news,covaxin registration,covaxin near me,covaxin vs covishield which is better,covaxin side effects,covaxin who approval,covaxin efficacy,Bharat biotech,bharat biotech vaccine,bharat biotech covaxin,bharat biotech ceo,bharat biotech covid vaccine,bharat biotech company

Bharat Biotech a global leader in vaccine innovation, developing vaccines for infectious diseases, ramped up of additional manufacturing capacities for COVAXIN.

The company plans to produce 200 million doses of COVAXIN per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety. Product availability at Ankleshwar to commence from Q4 2021.

Bharat Biotech had already deployed multiple Production lines at its Hyderabad & Bengaluru campuses, Adding Chiron Behring to this line up of high containment BSL rated GMP facilities that are required to manufacture COVAXIN”. This effectively takes the volumes upto – 1 Billion doses per Annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety.

About Bharat Biotech :

Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 16 vaccines, 4 bio-therapeutics, registrations in more than 123 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution.

Having delivered close to 5 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (JENVAC®), Rabies, Chikungunya, Zika, Cholera, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid. Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC, and Typbar TCV combatting polio, rotavirus, typhoid infections, respectively. The acquisition of Chiron Behring Vaccines, has positioned Bharat Biotech as the world’s largest rabies vaccine manufacturer with Chirorab and Indirab”.

RELATED ARTICLES
- Advertisment -